Business
OTC Markets Group Welcomes Newly Verified OTCQB Companies – Jan. 6
OTC Markets Group Welcomes Newly Verified OTCQB Companies – Jan. 6.
About this update from Rafina Innovations Inc.
[{"type":"text","content":"OTC Markets Group Inc. (OTCQX: OTCM), operator of Open, Transparent and Connected financial marketplaces, today announced the following companies are verified for trading on OTCQB®, the venture marketplace for entrepreneurial and development stage companies, effective January 6, 2015: AmbiCom Holdings, Inc. (OTCQB: ABHI) – AmbiCom delivers its medical device OEM modules to many global medical device companies, including Cardinal Health/Carefusion, Siemens, Draeger and Roche.AmbiCom is approved to continue trading on OTCQB.HCi VioCare (OTCQB: VICA) – HCi VioCare is aiming at creating the first state-of-the-art chain of Prosthetics & Orthotics (P&O) and Diabetic Foot clinics in Europe, with global reach, with a holistic approach regarding rehabilitation services to the physically impaired. The company is operating under the strict British standards and will be certified by the International Society of P&O. HCi VioCare is approved to continue trading on OTCQB.OncoSec Medical Incorporated (OTCQB: ONCS) – OncoSec Medical is a biopharmaceutical company developing its proprietary DNA-based intratumoral cancer immunotherapy technology, ImmunoPulse. OncoSec Medical's core technology is designed to enhance the local delivery and uptake of DNA IL-12 and other DNA-based agents that target tumor-induced immune subversion pathways. ImmunoPulse is a therapeutic approach that utilizes an electroporation delivery device in combination with DNA-encoded immune target modulators to treat cancer. Clinical studies of ImmunoPulse have demonstrated that the therapy is well-tolerated and preliminary evidence of anti-tumor activity has been observed, including the potential to initiate an immune response without the toxicities associated with systemic treatments. OncoSec Medical's lead program is evaluating ImmunoPulse for the treatment of metastatic melanoma. A Phase 2b study is in development to evaluate ImmunoPulse in combination with a checkpoint inhibitor, called anti-PD1 (pembrolizumab), for the treatment of metastatic melanoma and is being conducted in collaboration with several prominent academic medical centers. The company is also focused on identifying and developing new DNA-encoded proteins that target key pathways of tumor-induced immune subversion, investigating addit...